Neurocrine Biosciences
Encyclopedia
Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California
. The company tooks its name from the original focus on therapies for neurological and endocrine disease
s and disorders.
The company endured a significant setback on May 16, 2006 when the Food and Drug Administration
(FDA) denied approval for the 15-milligram dose of Indiplon
, a medication to treat insomnia. Neurocrine had developed the drug and was seeking to market it with partner, Pfizer
. Announcement of the setback led to a 62% drop in stock price. Subsequent disclosures related to attempts to overcome this major setback caused a further drop in the stock by 30% in November 2006.
Lacking approval for Indiplon, the company laid off a 200-member sales force in July, 2006 and 100 employees across all areas of the company on August 7, 2006. It announced a further cut of half the remaining workforce in December 2007, and a fourth quarter loss of $128 million, including a $94 million write-off.
But recently the company has recovered the long term hope for recovery. All started on the 25th of May, 2010 when the shares jumped nearly 25% after the company announced its drug to treat endometriosis had achieved its main and secondary goals in a study.
The drug, called elagolix, reportedly showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation as well as painful intercourse. And the shares of the company were up 69 cents to $3.40 on May the 25th trading, hitting a 52-week high of $4.23 early in the trading session.
But since that the stock has climbed from $4.23 to $6.16 at 25 June, 2010. And the expectatives for NBIX has raised about the elagolix trial success and of the sign for development deal with Boehringer. and Abbott Laboratories.
California
California is a state located on the West Coast of the United States. It is by far the most populous U.S. state, and the third-largest by land area...
. The company tooks its name from the original focus on therapies for neurological and endocrine disease
Disease
A disease is an abnormal condition affecting the body of an organism. It is often construed to be a medical condition associated with specific symptoms and signs. It may be caused by external factors, such as infectious disease, or it may be caused by internal dysfunctions, such as autoimmune...
s and disorders.
The company endured a significant setback on May 16, 2006 when the Food and Drug Administration
Food and Drug Administration
The Food and Drug Administration is an agency of the United States Department of Health and Human Services, one of the United States federal executive departments...
(FDA) denied approval for the 15-milligram dose of Indiplon
Indiplon
Indiplon is a nonbenzodiazepine, hypnotic sedative being developed in 2 formulations - an immediate release product for sleep onset and a modified-release version for sleep maintenance.- Mode of action :...
, a medication to treat insomnia. Neurocrine had developed the drug and was seeking to market it with partner, Pfizer
Pfizer
Pfizer, Inc. is an American multinational pharmaceutical corporation. The company is based in New York City, New York with its research headquarters in Groton, Connecticut, United States...
. Announcement of the setback led to a 62% drop in stock price. Subsequent disclosures related to attempts to overcome this major setback caused a further drop in the stock by 30% in November 2006.
Lacking approval for Indiplon, the company laid off a 200-member sales force in July, 2006 and 100 employees across all areas of the company on August 7, 2006. It announced a further cut of half the remaining workforce in December 2007, and a fourth quarter loss of $128 million, including a $94 million write-off.
But recently the company has recovered the long term hope for recovery. All started on the 25th of May, 2010 when the shares jumped nearly 25% after the company announced its drug to treat endometriosis had achieved its main and secondary goals in a study.
The drug, called elagolix, reportedly showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation as well as painful intercourse. And the shares of the company were up 69 cents to $3.40 on May the 25th trading, hitting a 52-week high of $4.23 early in the trading session.
But since that the stock has climbed from $4.23 to $6.16 at 25 June, 2010. And the expectatives for NBIX has raised about the elagolix trial success and of the sign for development deal with Boehringer. and Abbott Laboratories.